Antiparasitics acting on endo- or ectoparasites represent the second largest segment of the global animal health market, accounting for 23% of market share. However, relatively few novel antiparasitic agents have been introduced into the market during recent decades. One exception, and a groundbreaking 21st century success story, are the isoxazolines, whose full potential has not yet been entirely explored. Unfortunately, resistance issues are present across most parasitic diseases, which generates a clear market need for novel resistance-breaking antiparasitics with new modes/mechanisms of action. Recent advances in science and technologies strongly suggest that the time is right to invest in new modalities such as parasitic vaccines or in environmentally friendly interventions.

作用于内寄生虫或体外寄生虫的抗寄生虫药物是全球动物保健市场的第二大部分，占市场份额的23％。然而，在最近的几十年中，相对很少的新型抗寄生虫剂被引入市场。异恶唑啉是一种例外情况，是21世纪具有开创性的成功故事，其全部潜力尚未得到充分挖掘。不幸的是，大多数寄生虫疾病都存在抗药性问题，这引起了对具有新的作用方式/作用机理的新型抗药性抗寄生虫药的明确市场需求。科学技术方面的最新进展强烈表明，现在是投资新形式（如寄生虫疫苗）或环保干预措施的合适时机。